Menu Search
Equities

Plus Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
XMP0:MUN

Plus Therapeutics Inc

Actions
  • Price (EUR)1.14
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+4.95%
  • Beta0.7907
Data delayed at least 15 minutes, as of Feb 24 2025 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

  • Revenue in USD (TTM)5.26m
  • Net income in USD-20.58m
  • Incorporated1997
  • Employees21.00
  • Location
    Plus Therapeutics Inc4200 Marathon Blvd., Suite 200AUSTIN 78756United StatesUSA
  • Phone+1 (858) 458-0900
  • Fax+1 (302) 636-5454
  • Websitehttp://www.plustherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.